Singapore - English - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - alogliptin benzoate; pioglitazone hcl - tablet, film coated - alogliptin benzoate 12.5 mg; pioglitazone hcl 30 mg

Singapore - English - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - alogliptin benzoate; pioglitazone hcl - tablet, film coated - alogliptin benzoate 25 mg; pioglitazone hcl 15 mg

Singapore - English - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - alogliptin benzoate; pioglitazone hcl - tablet, film coated - alogliptin benzoate 25 mg; pioglitazone hcl 30 mg

Israel - English - Ministry of Health

takeda israel ltd - albumin human - solution for infusion - albumin human 200 mg / 1 ml - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.

Israel - English - Ministry of Health

takeda israel ltd - albumin human - solution for infusion - albumin human 50 mg / 1 ml - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 3000 iu - injection, diluent for - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrands disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 2000 iu - injection, diluent for - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 1500 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 1000 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 500 iu - diluent, not applicable - excipient ingredients: water for injections - advate is indicated or use in haemophilia a for prevention and control of haermorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von wllebrand's disease